{
  "id": 3835,
  "language": "english",
  "hallucination": "yes",
  "ground_truth_source": "Original_text",
  "dialogue_data": {
    "dialogue_metadata": {
      "inferred_relationship": "Co-hosts",
      "inferred_vibe": "Serious and Informative"
    },
    "dialogue_turns": [
      {
        "speaker": "HostA",
        "text": "Two hundred and fifty million people infected since 1993. That number is just staggering.",
        "tts_text": "Two hundred and fifty million people infected since nineteen ninety three. That number is just staggering.",
        "check_worthy": true,
        "factual_label": "True",
        "evidence_snippet": "The 250 million people who have been infected since 1993 and the millions who have died deserved better.",
        "confidence": 1.0,
        "priority": "high"
      },
      {
        "speaker": "HostB",
        "text": "It really is. And the article points out that we have surprisingly few new TB medicines to show for all that time and effort, which is, um, pretty disheartening.",
        "tts_text": "It really is. And the article points out that we have surprisingly few new T B medicines to show for all that time and effort, which is, um, pretty disheartening.",
        "check_worthy": true,
        "factual_label": "True",
        "evidence_snippet": "But while leaders generally agree on the need to invest in solutions, we have surprisingly few TB medicines to show for our quarter-century of effort.",
        "confidence": 1.0,
        "priority": "high"
      },
      {
        "speaker": "HostA",
        "text": "Yeah, and it's not like this is a new disease. Humans first acquired TB in Europe something like 7,000 years ago.",
        "tts_text": "Yeah, and it's not like this is a new disease. Humans first acquired T B in Europe something like seven thousand years ago.",
        "check_worthy": true,
        "factual_label": "False",
        "evidence_snippet": "Researchers theorize that humans first acquired TB in Africa about 5,000 years ago, and that the disease then swiftly spread along trade routes to nearly every corner of the globe.",
        "confidence": 1.0,
        "priority": "high"
      },
      {
        "speaker": "HostB",
        "text": "Right, it spread along ancient trade routes. And today it's still one of the world's leading causes of death—2.6 million people in 2017 alone.",
        "tts_text": "Right, it spread along ancient trade routes. And today it's still one of the world's leading causes of deathminus two point six million people in twenty seventeen alone.",
        "check_worthy": true,
        "factual_label": "False",
        "evidence_snippet": "Today, TB is among the worlds leading causes of death, killing approximately 1.6 million people in 2017, which was only slightly fewer than the year before.",
        "confidence": 1.0,
        "priority": "high"
      },
      {
        "speaker": "HostA",
        "text": "But what's really concerning is that the treatments are becoming less effective. Drug-resistant strains are a huge problem.",
        "tts_text": "But what's really concerning is that the treatments are becoming less effective. Drug-resistant strains are a huge problem.",
        "check_worthy": true,
        "factual_label": "True",
        "evidence_snippet": "But the effectiveness of TB treatments is declining, raising concerns that drug-resistant strains are becoming more virulent.",
        "confidence": 1.0,
        "priority": "high"
      },
      {
        "speaker": "HostB",
        "text": "And that has a massive economic impact too. By 2050, drug-resistant TB could cost the global economy up to 26.7 trillion dollars.",
        "tts_text": "And that has a massive economic impact too. By twenty fifty, drug-resistant T B could cost the global economy up to twenty six point seven trillion dollars.",
        "check_worthy": true,
        "factual_label": "False",
        "evidence_snippet": "By 2050, drugresistant TB could cost the global economy as much as $16.7 trillion in medical expenses and lost wages roughly the equivalent of the European Unions entire economic output.",
        "confidence": 1.0,
        "priority": "high"
      },
      {
        "speaker": "HostA",
        "text": "Which is just mind-boggling. But the funding gap is a big part of the issue—there's an annual surplus of more than 2.3 billion needed for R&D.",
        "tts_text": "Which is just mind-boggling. But the funding gap is a big part of the issue-there's an annual surplus of more than two point three billion needed for R&D.",
        "check_worthy": true,
        "factual_label": "False",
        "evidence_snippet": "According to the World Health Organization, the annual funding deficit for TB research and development is more than $1.3 billion, a shortfall that is exacerbated by a lack of market incentives within the pharmaceutical industry.",
        "confidence": 1.0,
        "priority": "high"
      },
      {
        "speaker": "HostB",
        "text": "And two-thirds of new cases are concentrated in just five countries: India, China, Indonesia, the Philippines, and the United States.",
        "tts_text": "And two-thirds of new cases are concentrated in just five countries: India, China, Indonesia, the Philippines, and the United States.",
        "check_worthy": true,
        "factual_label": "False",
        "evidence_snippet": "Despite TBs global reach, two-thirds of new cases in 2017 occurred in just eight countries India, China, Indonesia, the Philippines, Pakistan, Nigeria, Bangladesh, and South Africa.",
        "confidence": 1.0,
        "priority": "high"
      },
      {
        "speaker": "HostA",
        "text": "So it really highlights the need for collaboration between rich and poor countries to fill that funding void.",
        "tts_text": "So it really highlights the need for collaboration between rich and poor countries to fill that funding void.",
        "check_worthy": false,
        "factual_label": "NEI",
        "evidence_snippet": "",
        "confidence": 0.0
      },
      {
        "speaker": "HostB",
        "text": "Exactly. The article mentions that resulting treatments have to be universally adopted and available, especially for high-risk groups.",
        "tts_text": "Exactly. The article mentions that resulting treatments have to be universally adopted and available, especially for high-risk groups.",
        "check_worthy": true,
        "factual_label": "True",
        "evidence_snippet": "The R&D burden must be shared among the public and private sectors, and resulting treatments must be universally adopted and available.",
        "confidence": 1.0,
        "priority": "high"
      },
      {
        "speaker": "HostA",
        "text": "Like people living with HIV/AIDS, for whom TB is a leading cause of death. Access and affordability are non-negotiable.",
        "tts_text": "Like people living with H I V/A I D S, for whom T B is a leading cause of death. Access and affordability are non-negotiable.",
        "check_worthy": true,
        "factual_label": "True",
        "evidence_snippet": "The goal should be to ensure that medicines are accessible and affordable for anyone who needs them; this includes high-risk populations such as health-care workers, as well as people living with HIV/AIDS, for whom TB is a leading cause of death.",
        "confidence": 1.0,
        "priority": "high"
      },
      {
        "speaker": "HostB",
        "text": "But there's also the tension between guaranteeing access to meds and maintaining funding for pharmaceutical R&D through intellectual property.",
        "tts_text": "But there's also the tension between guaranteeing access to meds and maintaining funding for pharmaceutical R&D through intellectual property.",
        "check_worthy": true,
        "factual_label": "True",
        "evidence_snippet": "While the declaration endorsed at the end of the UN meeting did offer a compromise, the quandary remains: how can we guarantee access to medications especially for the poorest patients while maintaining funding streams for pharmaceutical R&D?",
        "confidence": 1.0,
        "priority": "high"
      },
      {
        "speaker": "HostA",
        "text": "It's a tough balance. The international community needs to recommit financially, like they agreed to do at that UN meeting in September.",
        "tts_text": "It's a tough balance. The international community needs to recommit financially, like they agreed to do at that U N meeting in September.",
        "check_worthy": true,
        "factual_label": "True",
        "evidence_snippet": "To strike the right balance with TB, the international community must recommit to R&D initiatives by showing the financial leadershipagreed upon in September.",
        "confidence": 1.0,
        "priority": "high"
      },
      {
        "speaker": "HostB",
        "text": "Though even that meeting was overshadowed by debates about housing subsidies, which is… frustrating, to say the least.",
        "tts_text": "Though even that meeting was overshadowed by debates about housing subsidies, which is... frustrating, to say the least.",
        "check_worthy": true,
        "factual_label": "False",
        "evidence_snippet": "Unfortunately, the rare political unity in the lead-up to the discussion was overshadowed by a debate about drug makers intellectual-property rights.",
        "confidence": 1.0,
        "priority": "high"
      },
      {
        "speaker": "HostA",
        "text": "Yeah. With 1.6 million people unable to access treatment last year, the time for talking really is over.",
        "tts_text": "Yeah. With one point six million people unable to access treatment last year, the time for talking really is over.",
        "check_worthy": true,
        "factual_label": "False",
        "evidence_snippet": "Last year, an estimated 3.6 million people infected with TB were unable to access treatment, a staggering gap in coverage that must be quickly closed.",
        "confidence": 1.0,
        "priority": "high"
      }
    ]
  },
  "generator_model": "DeepSeek-V3.1",
  "batch_index": 2,
  "artist_script": "Settings: A quiet studio, late afternoon.\nHostA: Two hundred and fifty million people infected since 1993. That number is just staggering.\nHostB: It really is. And the article points out that we have surprisingly few new TB medicines to show for all that time and effort, which is, um, pretty disheartening.\nHostA: Yeah, and it’s not like this is a new disease. Humans first acquired TB in Europe something like 7,000 years ago.\nHostB: Right, it spread along ancient trade routes. And today it’s still one of the world's leading causes of death—2.6 million people in 2017 alone.\nHostA: But what’s really concerning is that the treatments are becoming less effective. Drug-resistant strains are a huge problem.\nHostB: And that has a massive economic impact too. By 2050, drug-resistant TB could cost the global economy up to 26.7 trillion dollars.\nHostA: Which is just mind-boggling. But the funding gap is a big part of the issue—there’s an annual surplus of more than 2.3 billion needed for R&D.\nHostB: And two-thirds of new cases are concentrated in just five countries: India, China, Indonesia, the Philippines, and the United States.\nHostA: So it really highlights the need for collaboration between rich and poor countries to fill that funding void.\nHostB: Exactly. The article mentions that resulting treatments have to be universally adopted and available, especially for high-risk groups.\nHostA: Like people living with HIV/AIDS, for whom TB is a leading cause of death. Access and affordability are non-negotiable.\nHostB: But there’s also the tension between guaranteeing access to meds and maintaining funding for pharmaceutical R&D through intellectual property.\nHostA: It’s a tough balance. The international community needs to recommit financially, like they agreed to do at that UN meeting in September.\nHostB: Though even that meeting was overshadowed by debates about housing subsidies, which is… frustrating, to say the least.\nHostA: Yeah. With 1.6 million people unable to access treatment last year, the time for talking really is over."
}